Patent: 10,004,788
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,004,788
Title: | Treatment of ocular neovascularization using anti-VEGF proteins |
Abstract: | The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. |
Inventor(s): | Constable; Ian J. (Mosman Park, AU), Rakoczy; P. Elizabeth (Scarborough, AU), Lai; Chooi-May (Waterford, AU), Chalberg, Jr.; Thomas W. (Redwood City, CA) |
Assignee: | Avalanche Australia Pty Ltd. (Southbank, AU) |
Application Number: | 15/851,650 |
Patent Claims: | see list of patent claims |
Details for Patent 10,004,788
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | See Plans and Pricing | 2032-05-15 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | See Plans and Pricing | 2032-05-15 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | See Plans and Pricing | 2032-05-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |